Artificial intelligence enabled applications in kidney disease
- PMID: 32924202
- PMCID: PMC7891588
- DOI: 10.1111/sdi.12915
Artificial intelligence enabled applications in kidney disease
Abstract
Artificial intelligence (AI) is considered as the next natural progression of traditional statistical techniques. Advances in analytical methods and infrastructure enable AI to be applied in health care. While AI applications are relatively common in fields like ophthalmology and cardiology, its use is scarcely reported in nephrology. We present the current status of AI in research toward kidney disease and discuss future pathways for AI. The clinical applications of AI in progression to end-stage kidney disease and dialysis can be broadly subdivided into three main topics: (a) predicting events in the future such as mortality and hospitalization; (b) providing treatment and decision aids such as automating drug prescription; and (c) identifying patterns such as phenotypical clusters and arteriovenous fistula aneurysm. At present, the use of prediction models in treating patients with kidney disease is still in its infancy and further evidence is needed to identify its relative value. Policies and regulations need to be addressed before implementing AI solutions at the point of care in clinics. AI is not anticipated to replace the nephrologists' medical decision-making, but instead assist them in providing optimal personalized care for their patients.
© 2020 The Authors. Seminars in Dialysis published by Wiley Periodicals LLC.
Conflict of interest statement
SC is a student at Maastricht University Medical Center. SC, AL, CM, JWL, SK, FWM, and LAU are employees of Fresenius Medical Care. HZ and PK are employees of Renal Research Institute, a wholly owned subsidiary of Fresenius Medical Care. SC, PK, FWM, and LAU have share options/ownership in Fresenius Medical Care. PK receives honorarium from Up‐To‐Date and is on the Editorial Board of Blood Purification and Kidney and Blood Pressure Research. FWM has a directorship in FMC Management Board, Goldfinch Bio Board, and Vifor Fresenius Medical Care Renal Pharma Board. JPK and FMS have nothing to disclose.
Figures







References
-
- Usvyat L, Dalrymple LS, Maddux FW. Using technology to inform and deliver precise personalized care to patients with end‐stage kidney disease. Semin Nephrol. 2018;38:418‐425. - PubMed
-
- Topol EJ. High‐performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25:44‐56. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical